Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Hold” from Analysts

Tempus AI, Inc. (NASDAQ:TEM) has been given a consensus recommendation of “Hold” by the thirteen analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $87.20.

A number of research analysts have commented on the stock. Morgan Stanley upped their target price on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Needham & Company LLC upped their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Canaccord Genuity Group lowered their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. TD Cowen lowered Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. Finally, BTIG Research raised their price target on Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $74.10, for a total transaction of $12,319,125.00. Following the sale, the chief executive officer directly owned 9,008,033 shares in the company, valued at $667,495,245.30. This represents a 1.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew Polovin sold 12,874 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $75.00, for a total value of $965,550.00. Following the sale, the executive vice president directly owned 107,590 shares in the company, valued at $8,069,250. This represents a 10.69% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 761,582 shares of company stock valued at $51,997,831. Insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Cranbrook Wealth Management LLC acquired a new position in Tempus AI in the third quarter valued at approximately $25,000. Concord Wealth Partners raised its holdings in Tempus AI by 308.0% during the second quarter. Concord Wealth Partners now owns 408 shares of the company’s stock worth $26,000 after purchasing an additional 308 shares in the last quarter. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the 3rd quarter worth approximately $26,000. GAMMA Investing LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $28,000. Finally, Allworth Financial LP boosted its holdings in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after buying an additional 450 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Down 2.2%

Shares of NASDAQ TEM opened at $55.88 on Wednesday. The company has a market capitalization of $9.94 billion, a P/E ratio of -46.96 and a beta of 5.22. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The company has a 50 day simple moving average of $65.65 and a 200-day simple moving average of $73.80. Tempus AI has a 1 year low of $36.22 and a 1 year high of $104.32.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.